Abstract：【Objective】To explore the survival rate and safety of TCD and BCD in the treatment of multiple myeloma(MM).【Method】Seventy-two patients with MM were enrolled in our hospital. The patients were divided into A group and B group by treatment methods, with 36 cases in each group. The A group was treated with the TCD regimen and the B group was treated with the BCD regimen. The clinical efficacy and serum levels of β2-microglobulin(β2-MG), C-reactive protein(CRP), and serum creatinine(Cr) were compared between the two groups. The tumor markers such as antigen(CEA), carbohydrate antigen 125(CA125), neuron-specific enolase(NSE) and cytokeratin fragment antigen 21-1(CYFRA21-1) were compared as well between the two groups before and after treatment. The survival rate and incidence of adverse reactions between the two groups were analyzed.【Results】The total effective rate of 63.89%(23/36) in the A group was significantly lower than that in the B group(88.89%, 32/36)(P<0.05). The difference of Cr in the A group was significantly lower than that in the B group(P<0.05). After treatment, the β2-MG and CRP levels in the two groups were significantly lower (P< 0.05). However, there was no significant difference between the two groups in either before or after treatment(P>0.05). Compared to before treatment, levels of CEA, CA125 and NSE were significantly lower in both groups after the treatment(P<0.05). While there was no significant difference between the two groups in either before or after treatment with CEA, CA125 and NSE(P>0.05). The survival rate was similar; And the difference was not statistically significant(P>0.05). The total incidence of adverse reactions in the A group was 25.00% compared with 19.44% in the B group, and the difference was not statistically significant(P>0.05).【Conclusion】The BCD regimen is used in the treatment of newly diagnosed MM. The safety and survival rate are comparable to those of the TCD regimen. It is better than the TCD regimen and worthy of clinical attention.
2021, Vol. 38 
